Disputation: Judith Jing Wen Wong

Doctoral candidate Judith Jing Wen Wong at the Department of Pharmacy, Faculty of Mathematics and Natural Sciences, is  defending the thesis "Photochemical Strategies to Eliminate Cancer Cells" for the degree of Philosophiae Doctor.

Judith Jing Wen Wong

Photo: Øystein Horgmo, UiO

Trial lecture - time and place

10.12.2021, 10.15, Auditorium 2, Helga Eng

The Different Mechanisms of Cancer Drug Resistance

Conferral summary

Legemiddelleveringsmetoden fotokjemisk internalisering, PCI, bruker lys for å gjøre medisiner mer effektive. Denne avhandlingen undersøkte PCI i kombinasjon med både markedsførte og eksperimentelle kreftlegemidler hvor målet var å øke effektiviteten av legemidlene i resistente kreftceller. Resultatene viste lovende resultater av enkelte legemiddelkandidater, og har bidratt til økt innsikt i videreutvikling av nye PCI-baserte kreftbehandlinger.

Main research findings

Despite significant progress in cancer drug development over the last decade, drug resistance occurs in many cases, limiting the treatment efficacy and giving rise to relapses in cancer patients. There is, therefore, a need to develop new cancer treatment strategies that improve tumor response and disease control. One approach is the use of the light-facilitated drug delivery technology photochemical internalization (PCI). The PCI technology is based on photodynamic therapy (PDT), which requires a light-sensitive compound, a photosensitizer, and light for activation. Previous research has indicated that the drug efficacy in cancer cells increases in combination with PCI, particularly for large molecules such as macromolecules.

In this present work, Wong and colleagues studied the PCI-photosensitizer TPCS2a/Fimaporfin in combination with approved or experimental drugs in a preclinical setting. These results indicate that the small-molecule tyrosine kinase inhibitor sunitinib is not an optimal PCI candidate due to photodamage of the drug and an antagonistic effect on tumor-infiltrating T cells. On the other hand, light activation of TPCS2a combined with a bioactive lipid derivate or a checkpoint-blockade targeting immunotoxin indicated promising results. Overall, the presented discoveries lay the foundation for improved PCI-based cancer treatment.

Read more

Lys hjelper legemiddelet å angripa kreftcella (Titan, Dec. 3, 2021 (in Norwegian))


Published Nov. 26, 2021 10:00 AM - Last modified Dec. 7, 2021 11:48 AM